about
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.Vascular permeability in cerebral cavernous malformations.Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.Hormone therapy at early post-menopause increases cognitive control-related prefrontal activitySocial brains and divides: the interplay between social dominance orientation and the neural sensitivity to hierarchical ranks.Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.Endothelial TLR4 and the microbiome drive cerebral cavernous malformations.Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis.RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial.Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasisComprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypesPlasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional GrowthEditorial for "Ensemble Learning for Early-Response Prediction of Antidepressant Treatment in Major Depressive Disorder"Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sitesDistinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformationSurgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) ProcedureBiomarkers of cavernous angioma with symptomatic hemorrhageCerebral cavernous malformations form an anticoagulant vascular domain in humans and micePermissive microbiome characterizes human subjects with a neurovascular disease cavernous angiomaCommon transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation
P50
Q31119793-AFABA751-D98B-483B-A718-84196DE67B81Q36267403-97ED10F1-B517-4592-952D-EAE692923FE9Q37050968-9E904B29-A847-4735-87AF-E6CE4EDADFFDQ37099099-0A69AC9D-76C5-4786-AA0B-70D938C6599DQ37713006-23A36D69-C13E-41B2-B962-9F5053DA2D92Q37737997-74D9228D-0BA3-4C89-A899-BCB2D3632421Q38632703-F9985AA3-D44F-4BFD-BFEB-6990E1D1C533Q38640436-496B8D61-D831-4CB5-B7B5-080F73C9FC61Q38880171-D7594BDA-40A1-4EB1-9F2D-177A7FFB8E48Q40968561-AEE91249-CAA7-4F46-ADD7-3CB84F758F81Q46147842-9C83EF46-8BD0-472D-826E-8F6C8D5D9C26Q46180887-398FCE04-42F7-42B5-B382-7E0D4DE37E0CQ47222553-55642DAC-5A3D-4C7D-B2CD-230D80DA0D74Q48419319-349D5A56-055E-43F5-859D-6281CAE45BA4Q52098871-BB3EDB8F-2E1E-42B2-AB7F-182B5FAEA991Q52585802-2D3CC201-314E-4029-BF8C-AC8EB44D9370Q64106050-B3707AE3-CD47-49E9-9289-30C6CBC2C3ECQ64261882-A1B3A768-6AFE-419A-BC55-24F0BC88389FQ88547137-2DF76A54-1FBE-47D2-9F7A-81D00551F317Q89605372-A6572914-FAF2-4182-93A7-1F6A36EEAF65Q90085339-11FE1854-2F62-4073-A92B-213BD307AD2BQ91496209-F7F34229-6319-41D9-87E6-C8643DF51FFEQ92493721-6478F8B6-B402-493A-A223-BF1DFDF76521Q92884386-A03D175C-4517-4B61-BA21-A4B2B163980AQ93159519-0F0EDF17-873B-46D2-B525-EEB174D57ADBQ95933817-4E31BA30-892B-4C83-8CAD-A7832909CF17Q96582168-71B3D303-0814-4890-A907-B01E98FFB2CE
P50
description
investigador
@es
researcher
@en
name
Romuald Girard
@en
type
label
Romuald Girard
@en
prefLabel
Romuald Girard
@en
P31
P496
0000-0002-5893-9315